Key result
Immunization with a bivalent inactivated EV71 C4a and CVA16 vaccine mitigated paralytic signs and increased the survival rate to 100% following lethal viral challenges in Mongolian gerbils.
Why the study?
Because there are no efficient therapeutics for hand-foot-and-mouth disease, the development of a bivalent vaccine form is needed to provide broad coverage against coxsackievirus and enterovirus.
Does a bivalent inactivated EV71 C4a/CVA16 vaccine prevent viral infection and improve survival in Mongolian gerbils?
Does a bivalent inactivated EV71 C4a/CVA16 vaccine prevent viral infection and improve survival in Mongolian gerbils?
p-value: p=<0.0001
A bivalent inactivated EV71 C4a/CVA16 vaccine demonstrates efficacy in preventing infection, reducing viral load, and improving survival in a Mongolian gerbil model.
Bivalent HFMD vaccine candidate appears safe and effective in gerbils; leaves open translation to human trials.
Hand-foot-and-mouth disease (HFMD) is a viral infectious disease that occurs in children under 5 years of age. Its main causes are coxsackievirus (CV) and enterovirus (EV). Since there are no efficient therapeutics for HFMD, vaccines are effective in preventing the disease. To develop broad coverage against CV and EV, the development of a bivalent vaccine form is needed. The Mongolian gerbil is an efficient and suitable animal model of EV71 C4a and CVA16 infection used to investigate vaccine efficacy following direct immunization. In this study, Mongolian gerbils were immunized with a bivalent inactivated EV71 C4a and inactivated CVA16 vaccine to test their effectiveness against viral infection. Bivalent vaccine immunization resulted in increased Ag-specific IgG antibody production; specifically, EV71 C4a-specific IgG was increased with medium and high doses and CVA16-specific IgG was increased with all doses of immunization. When gene expression of T cell-biased cytokines was analysed, Th1, Th2, and Th17 responses were found to be highly activated in the high-dose immunization group. Moreover, bivalent vaccine immunization mitigated paralytic signs and increased the survival rate following lethal viral challenges. When the viral RNA content was determined from various organs, all three doses of bivalent vaccine immunization were found to significantly decrease viral amplification. Upon histologic examination, EV71 C4a and CVA16 induced tissue damage to the heart and muscle. However, bivalent vaccine immunization alleviated this in a dose-dependent manner. These results suggest that the bivalent inactivated EV71 C4a/CVA16 vaccine could be a safe and effective candidate HFMD vaccine.
No takes yet. Share an insight, caveat, or question.
Yi et al. (2023) studied Hand-foot-and-mouth disease (EV71 and CVA16 infection). Bivalent inactivated EV71 C4a and CVA16 vaccine vs. Vehicle was evaluated on Survival rate following lethal viral challenge (p=<0.0001). Immunization with a bivalent inactivated EV71 C4a and CVA16 vaccine mitigated paralytic signs and increased the survival rate to 100% following lethal viral challenges in Mongolian gerbils.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: